Slone Partners - Slone Partners - Laboratory Headlines

Contact Slone Partners

	Call us today toll free at 888-424-7800 to discuss your laboratory business hiring needs
	Sign up for our monthly newsletter
	Browse our current job opportunities and apply for a position

We will make the right diagnosis for you

Alberta’s Next Round of Clinical Laboratory Consolidation Alarms Pathologists
Plans are to centralize all cervical cancer screening in just two Alberta medical laboratories

Total Laboratory Automation Gives Clinical Pathology Labs More Ways to Achieve Significant Efficiency and Savings
TLA and other laboratory automation solutions help clinical labs cope with shortage medical technologists

Molecular Diagnostics Laboratory in a Suitcase Travels to Farms to Test Livestock
New molecular point-of-care testing systems already being tested in several African countries

Details Issued Today on $1 Billion in Biotech Tax Credits and Grants
Small to Mid-Sized Firms Should Waste No Time in Applying for Key Federal Incentives, Attorney Says.

Three Reasons to Invest in Personalized Medicine
Iris BioTechnologies (IRSB), Genomic Health (GHDX) and Affymetrix (AFFX) are three of the major players in one of the hottest fields in biotechnology today – personalized and targeted medicine. While Affymetrix, the industry leader in microarray technology, has dominated the research arena, Genomic Health has helped bring molecular diagnostics technology to the clinician paving the way for an early adoption of Iris’s more advanced technologies, products, and services.

Rosetta Genomics to Present at the 6th Annual Rodman and Renshaw ...
Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of ...

GE Healthcare Forms Strategic Alliance with Cardiovascular Genomic Diagnostic Company, CardioDx
... Fund targets three broad areas for investment: Broad-based Diagnostics, including imaging, home health, patient monitoring, molecular diagnostics, ...

Discovery Of New Approach For Identifying Smokers At Highest Risk For Developing Lung Cancer
Spira is one of the founders of Allegro Diagnostics Inc. , a molecular diagnostics company that plans to market the gene expression biomarker. Source: Gina DiGravioBoston University Medical Center Any medical information published on ...

PerkinElmer Enters Into Agreement to Acquire Signature Genomic Laboratories, LLC
Acquisition brings new diagnostic services to global leader in pre-natal and newborn health screening.

Medical Diagnostics: Five Health Care Reform Beneficiaries
"There are also people who avoid the doctor's office, not because they're afraid of needles, but because they can't afford it," says growth stock specialist Marc Lichtenfeld.

AACR 2009: Measuring Circulating Tumor Cells Is Clinically Useful, New Technique Promises to Be Faster

Predictive Biosciences to Present Novel Combination Approach to Molecular Cancer Diagnostics at 2010 Genitourinary Cancers Symposium
Predictive Biosciences today announced that the Company will be presenting its novel Multi-Analyte Diagnostic Readout (MADR™) approach to the development of a non-invasive, urinary biomarker based assay for the detection of bladder cancer during the 2010 Genitourinary Cancers Symposium (GU Symposium), being held March 5-7 in San Francisco. The GU Symposium is co-sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO). The MADR research, which combines protein and DNA biomarkers to identify with high certainty a group of bladder cancer patients who are disease free and could be excluded from undergoing invasive procedures, was conducted under collaboration agreements with Lahey Clinic Medical Center and Mayo Clinic.

BHL litigation against Health Diagnostic Laboratory: Celera addresses business impact
Celera Corporation (NASDAQ:CRA) today provided information on litigation filed by Berkeley HeartLab, Inc. (“BHL”), Celera’s wholly-owned subsidiary, against Health Diagnostic Laboratory, Inc. and several former employees of BHL, including five sales representatives who left the Company on January 1, 2010, and two former laboratory employees. BHL has filed a complaint seeking injunctive relief and damages in the United States District Court for the Eastern District of Virginia. In the litigation, BHL has asserted a number of contractual, tort and statutory claims against the defendants, including claims for misappropriation of trade secrets and tortious interference with BHL’s client relationships. The defendants’ activities have been concentrated in the Southeast, which historically has been the highest-volume sales territory for BHL.

A better genetic test for autism - In largest study to date, chromosomal microarray analysis picks up more abnormalities than current tests
A large study from Children's Hospital Boston and the Boston-based Autism Consortium finds that a genetic test that samples the entire genome, known as chromosomal microarray analysis, has about three times the detection rate for genetic changes related to autism spectrum disorders (ASDs) than standard tests. Publishing in the April issue of Pediatrics (and online March 15), the authors urge that CMA become part of the first-line genetic work-up for ASDs.

Merger of Spectrum Laboratory Network and Carilion Labs Creates Big Clinical Laboratory Company
Spectrum Laboratory Network of Greensboro, North Carolina announced a merger with Carilion Labs of Roanoke, Virginia. The combined enterprise will have annual revenue of approximately $300 million and immediately becomes one of the nation’s larger clinical laboratory companies.